Supervisor’s research interests

Study of molecular mechanisms of proteasome machinery, including specific inhibitors of immunoproteasome for the treatment of autoimmune diseases, investigation of ubiquitin metabolism and global profiling of the cellular ubiquitinome, probing of the ubiquitin-proteasome system utilizing genome editing techniques.

Research highlights

We developed technique for the ubiquitin fluorescence tracking and now are using this methodology to provide comprehensive understanding of ubiquitin-proteasome system dynamics on the previously unreachable state of the art.

Main publications

• Kudriaeva A, et al. et al, Charge-mediated proteasome targeting. FASEB J. (2019)
• A. V. Stepanov et al., Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma. Sci. Adv. (2018).
• Lomakin Y et al., Diagnostics of autoimmune neurodegeneration using fluorescent probing. Sci Rep. (2018)
• Ivanova VV, et al. Divergent Immunomodulation Capacity of Individual Myelin Peptides-Components of Liposomal Therapeutic against Multiple Sclerosis. Front Immunol. (2017)
• Lomakin, et al., Exposure to the Epstein-Barr viral antigen LMP1 induces myelin-reactive antibodies in vivo, Front Immunol, (2017)
• Terekhov, S.S. et al. Microfluidic droplet platform for ultrahigh-throughput single-cell screening of biodiversity PNAS (2017)
• Belogurov, A., Jr. et al., CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study, Neurotherapeutics (2016)
• Belogurov, A., Jr. et al., Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity FASEB J. (2015)
• Belogurov Jr., A., et al Multiple sclerosis autoantigen myelin basic protein escapes control by ubiquitination during proteasomal degradation, JBC (2014)